« Return to News | Clinical Intelligence

ImmunoGen initiates phase I trial in non-Hodgkin's lymphoma

Wednesday, April 18, 2012 12:14 PM

ImmunoGen, a biotechnology company that develops anticancer therapeutics using Targeted Antibody Payload (TAP) technology, has begun a phase I trial of its IMGN529 anticancer compound.

The phase I trial will evaluate the safety, tolerability, pharmacokinetic profile and anticancer activity of escalating doses of IMGN529 in 55 patients with relapsed or relapsed/refractory, CD37-expressing non-Hodgkin's lymphoma (NHL) to establish the dose for future clinical trials. NHL is typically treated with the anticancer antibody, rituximab and chemotherapy. IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in preclinical testing. Attached to this antibody is a potent ImmunoGen cell-killing agent, DM1. The antibody serves to kill the cancer cells through multiple antibody-mediated mechanisms and also deliver the DM1 specifically to the cancer cells for additional, targeted anticancer potency.

"The phase I trial now underway, together with our market research, is expected to provide the information needed to define a clear development path for IMGN529 in NHL," said James O'Leary, MD, vice president and CMO. "With its unique profile, we believe IMGN529 has the potential to be an important new therapy for the treatment of key B-cell malignancies."

Patients with follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma—the more common types of NHL—are still eligible for enrollment.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.